Preclinical modeling in GBM PDX xenografts to guide clinical development of lisavanbulin - a novel tumor checkpoint controller targeting microtubules.
Danielle M BurgenskeSurabhi TaleleJenny L PokornyAnn C MladekKatrina K BakkenBrett L CarlsonMark A SchroederLihong HeZeng HuGautham GampaMatthew L KoselPaul A DeckerGaspar J KitangeAnne Schmitt-HoffmannFelix BachmannRachael A VaubelJeanette E Eckel-PassowCaterina GianniniPaul McSheehyHeidi A LaneWilliam F ElmquistJann N SarkariaPublished in: Neuro-oncology (2021)
Lisavanbulin demonstrated excellent brain penetration, significant extension of survival alone or in RT or RT/TMZ combinations and was associated with mitotic arrest. These data provide a strong clinical rationale for testing lisavanbulin in combination with RT or RT/TMZ in GBM patients.